Aptevo Therapeutics Inc. announced a 93% clinical benefit rate for its mipletamig triplet therapy in evaluable frontline acute myeloid leukemia (AML) patients with TP53 mutations. Among 14 evaluable patients, 13 experienced clinical benefit, including an 11-patient complete remission or complete remission with incomplete hematologic recovery (CR/CRi) rate of 79%. These results nearly double the published venetoclax plus azacitidine outcomes for this difficult-to-treat population. The RAINIER study is expected to complete dose optimization by year-end, with regulatory interaction planned for the first half of 2027. Aptevo Therapeutics Inc. operates in the biotechnology industry, developing novel multispecific immuno-oncology therapeutics.

Aptevo Therapeutics Inc. reported financial results for the quarter ended June 30, 2026, highlighting strong clinical data for its lead candidate mipletamig in frontline acute myeloid leukemia (AML). The RAINIER trial showed an 87% clinical benefit rate and 81% remission rate across 31 evaluable patients. The company secured a $1.5 million non-dilutive grant to advance APVO451, appointed Mary J. Janatpour as Chief Scientific Officer, and entered a 50/50 collaboration with Niowave for radiopharmaceutical development. Cash and cash equivalents totaled $9.8 million at quarter-end. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company developing novel multispecific immunotherapies for the treatment of cancer.

Aptevo Therapeutics Inc. closed a financing transaction on August 13, 2026, raising approximately $4.5 million in gross proceeds for working capital and general corporate purposes. The company entered into warrant inducement letters with holders of existing warrants issued between December 2024 and June 2025, requiring the exercise of up to 254,922 warrants at a reduced price of $4.03 per share. In exchange for these exercises, Aptevo issued new unregistered warrants (Inducement Warrants) to purchase up to 1,274,610 shares at $4.03 per share, exercisable after stockholder approval and expiring five years later. Simultaneously, the company sold up to 861,708 shares of common stock (or pre-funded warrants) in a private placement PIPE at $4.03 per share, accompanied by Common Warrants to purchase up to 4,308,540 additional shares at the same exercise price. Roth Capital Partners acted as the exclusive placement agent for a 7% fee plus expense reimbursement. Aptevo Therapeutics Inc. is a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics.

Aptevo Therapeutics Inc. announced a new solid tumor strategy on July 27, 2026, centered on a patent application for a proprietary Nectin-4 x PD-L1 dual-targeting backbone. This platform-derived innovation is designed to support multiple therapeutic approaches, including radiopharmaceuticals, T-cell engagers, and other immune-based therapies. The company intends to use this reusable targeting architecture to expand its oncology pipeline, enhance tumor localization, and increase opportunities for strategic partnerships with large pharmaceutical companies. Aptevo is a clinical-stage biotechnology company developing multispecific immuno-oncology therapeutics.

Aptevo Therapeutics Inc. entered into a Grant Award Agreement with the Andy Hill Cancer Research Endowment (CARE) Fund on June 29, 2026, to receive $1,499,951.00 in reimbursement-based funding. The funds are intended to support Investigational New Drug (IND)-enabling studies for APVO451, a trispecific antibody candidate for solid tumor indications, through an expected project period ending in June 2028. Aptevo Therapeutics Inc. is a biotechnology company focused on developing therapeutic antibody candidates for cancer treatment.